Every 8-K that Quanterix (QTRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow QTRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QTRX filings page.
Quanterix Corporation reported second-quarter 2026 revenue of $32.9 million, up 34% from $24.5 million a year earlier, led by product and service growth. GAAP gross margin was 38.5%, while adjusted gross margin improved to 47.9%. The company recorded a net loss of $48.9 million versus $30.0 million, driven largely by a $26.9 million goodwill impairment related to the Akoya acquisition and other restructuring costs. Adjusted EBITDA loss narrowed to $10.0 million from $13.7 million, and adjusted cash usage in the quarter was $4.0 million.
Quanterix ended the quarter with $96.9 million in cash, cash equivalents, marketable securities and restricted cash, and has realized $85 million of annualized cost synergies from the Akoya integration. The company revised its 2026 outlook, cutting expected revenue to $142–148 million from $169–173 million, lowering its non-GAAP gross margin range to 48–50%, and pushing expected cash-flow breakeven to 2027 with a projected year-end 2026 cash balance of about $80 million and no debt. Operationally, Quanterix advanced its Alzheimer’s diagnostics strategy, including Anthem coverage for its Lucent AD® Complete test, new biomarker launches, and selection as a co-investigator in a major Parkinson’s biomarker program. The company also strengthened its leadership team, appointing Jim Gute as Chief Commercial Officer to improve commercial execution.
Quanterix Corporation reported the results of its 2026 annual shareholder meeting held on June 9, 2026. Stockholders elected William P. Donnelly and Ivana Magovčević-Liebisch, Ph.D., J.D. as independent directors for one-year terms and approved the advisory vote on executive compensation.
Shareholders also ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. However, they did not approve an amendment and restatement of the 2017 Employee, Director and Consultant Equity Incentive Plan that would have extended the plan through June 9, 2031.
Quanterix Corporation has appointed Jason Faessler as its new Chief Financial Officer and Treasurer, with employment expected to begin on June 22, 2026. He brings senior finance leadership experience from Bruker Corporation, PAREXEL, EMC and Harvard Business Publishing, with a background in strategic planning and operational finance.
Under an employment agreement dated May 31, 2026, Faessler will receive an initial annual base salary of $475,000, a $200,000 cash sign-on bonus, and is eligible for an annual performance bonus targeted at up to 50% of base salary. He will also receive restricted stock units equal to 0.30% of Quanterix’s outstanding common shares on his start date, vesting in four equal annual installments.
If his employment is terminated without Cause or he resigns for Good Reason, Faessler is entitled to 12 months of base salary continuation, a pro-rated target bonus, and subsidized health benefits. If such a termination occurs in connection with a Change-in-Control, he also receives full vesting of outstanding unvested equity awards.
Quanterix Corporation appointed Anthony Catalano as its new Chief Operating Officer effective May 14, 2026. He brings prior leadership experience from Flagship Pioneering, Akoya Biosciences, Bruker Cellular Analysis and Revvity.
Under his employment agreement, Catalano will receive a $400,000 annual base salary, a $50,000 cash sign-on bonus and eligibility for an annual performance bonus targeted at up to 50% of base salary. He also received restricted stock units equal to 0.30% of Quanterix common shares outstanding on his start date, vesting in four equal annual installments.
If the company terminates him without Cause or he resigns for Good Reason, he is entitled to six months of base salary continuation, a pro-rated target bonus for the year of termination and subsidized health benefits. If such a termination occurs in connection with a Change-in-Control, salary continuation extends to nine months and all outstanding time-based equity awards become fully vested. Michael Miller, the former Chief Operating Officer, has moved to the role of Chief Technology and Products Officer.
Quanterix Corporation announced that Chief Financial Officer and Treasurer Vandana Sriram will leave the company, with her role ending on June 15, 2026. She will stay through that date to support a smooth transition while the company conducts a search for her successor with an executive search firm.
Under her employment agreement, Ms. Sriram will receive 12 months of base salary, an amount equal to her annual target bonus for 2026, and subsidized health benefits for 12 months. The company states that her departure is not related to any disagreements regarding accounting practices, financial statements, internal controls, or operations, and highlights that Quanterix remains on solid financial footing with a focus on cash flow breakeven and synergy targets.
Quanterix Corporation reported first-quarter 2026 revenue of $36.4 million, up 20% from $30.3 million a year earlier, driven by product and service growth across its Simoa and spatial biology platforms. GAAP gross margin was 42.7%, while adjusted gross margin improved to 50.9% from 49.7%.
The company posted a GAAP net loss of $17.5 million (or $0.37 per share), modestly better than the $20.5 million loss in 2025, and an adjusted EBITDA loss of $9.8 million versus $11.3 million. Quanterix ended the quarter with $102.6 million in cash, cash equivalents, marketable securities and restricted cash.
Management highlighted progress on integrating Akoya Biosciences, citing $85 million of cost synergies realized and a terminated off-market diagnostics contract that drove significant one-time charges and income. The Alzheimer’s diagnostics franchise continues to expand, with several clinical utility studies expected to complete and an FDA decision on a 510(k) application anticipated in the second half of 2026.
For full-year 2026, Quanterix reaffirmed revenue guidance of $169–$174 million, GAAP gross margin of 41–45% and adjusted gross margin of 49–53%. The company continues to expect cash flow breakeven in the second half of 2026 and to finish the year with roughly $100 million in cash and no debt.
Quanterix reported fourth quarter and full-year 2025 results and issued its 2026 outlook. Q4 2025 revenue was $43.9 million, up from $35.2 million, while full-year revenue was $138.9 million versus $137.4 million in 2024. GAAP gross margin fell to 46.8% for 2025 from 60.5%, and the company recorded a net loss of $107.2 million, wider than $38.5 million a year earlier. Adjusted EBITDA loss was $44.9 million.
Quanterix ended 2025 with $121.6 million in cash, cash equivalents, marketable securities and restricted cash and has implemented $74 million of an $85 million cost-synergy target tied to the Akoya acquisition. The company submitted a 510(k) to the FDA for its multi-analyte Alzheimer’s blood test and CMS set a $897 reimbursement rate for the LucentAD Complete test. For 2026, Quanterix guides to revenue of $169–$174 million, GAAP gross margin of 45–49%, adjusted gross margin of 49–53%, and expects to reach cash flow breakeven in the second half of 2026 and exit the year with about $100 million in cash and no debt.
Quanterix Corporation announced a leadership change, with President and CEO Masoud Toloue, Ph.D., entering a separation agreement under which his employment and Board service end effective January 19, 2026. He will receive severance consistent with a termination without cause, accelerated vesting of equity that would have vested by April 30, 2026, and extended time to exercise vested stock options through December 31, 2026.
The Board appointed Everett Cunningham as President and CEO, and as a Class II director with a term ending at the 2028 annual meeting, effective January 19, 2026. His employment agreement provides a $750,000 annual base salary, an annual bonus target up to 100% of salary, and a $600,000 sign-on cash payment subject to repayment conditions. He also received time-based RSUs covering 1,070,000 shares and performance-based RSUs covering 813,750 shares, which vest over time and upon stock price hurdles at $10, $15, and $20 per share or in connection with certain change-in-control events. The company also furnished a press release that includes expectations for select full-year 2025 financial results.
Quanterix Corporation reported changes to its Board of Directors. Long-time directors Paul Meister and David Walt, Ph.D. retired from the Board and all its committees, and their departures were stated as not arising from any disagreement with the company’s operations, policies, or practices.
The Board appointed Garret Hampton, Ph.D., as a Class II director with a term expiring at the 2028 annual meeting, and Alan Sachs, M.D., Ph.D., as a Class I director with a term expiring at the 2027 annual meeting. Dr. Hampton will serve on the Audit and Compensation Committees, while Dr. Sachs will serve on the Compensation Committee.
Both new directors will receive an annual cash retainer of $50,000 plus additional committee retainers. Each will receive an initial restricted stock unit grant equal to 0.1% of Quanterix’s outstanding common shares on the grant date, vesting over three years, and ongoing annual RSU grants equal to 0.05% of outstanding shares, vesting after one year.
Quanterix Corporation (QTRX) furnished an Item 2.02 update announcing financial results for the third quarter ended September 30, 2025. The company provided an earnings press release and accompanying presentation slides as exhibits. The information in this item, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.
Exhibits include: 99.1 Earnings Release (November 10, 2025) and 99.2 Earnings Call Slides. The report was signed by Chief Financial Officer Vandana Sriram.
Quanterix Corporation reported results from its 2025 Annual Meeting of Stockholders held on September 29, 2025. Stockholders elected Myla Lai-Goldman, M.D., Masoud Toloue, Ph.D., and David R. Walt, Ph.D. to three-year terms on the board of directors, each receiving more than 29.7 million votes in favor.
Investors also approved, on an advisory basis, the compensation of the company’s named executive officers, with about 30.3 million votes for and 5.5 million against. KPMG LLP was ratified as independent registered public accounting firm with over 40.0 million votes for and minimal opposition.
Stockholders backed several governance changes. They approved an amendment to declassify the board of directors and separate amendments to remove supermajority stockholder vote requirements to change certain charter provisions and the company’s bylaws, each receiving approximately 35.6 million votes in favor.
Quanterix Corporation adjourned its shareholder meeting and scheduled an adjourned session for shareholders who pre-register by 10:00am ET on September 28, 2025 at the provided registration URL. The company reported that at the original meeting time shareholders who voted were overwhelmingly in favor of two proposals to eliminate supermajority vote requirements, with 99% of votes cast supporting those two proposals. However, the shares that voted in favor represented 74.8% of the company’s common stock outstanding. The filing is signed by Vandana Sriram, Chief Financial Officer, and lists contact and filing references.
Quanterix Corporation filed an amendment to a current report to provide additional financial details related to its acquisition of Akoya Biosciences, Inc. The acquisition of Akoya was completed on July 8, 2025 under an Amended and Restated Agreement and Plan of Merger dated April 28, 2025 among Quanterix, a merger subsidiary, and Akoya.
This amendment adds unaudited pro forma condensed combined financial statements for Quanterix and Akoya for the year ended December 31, 2024 and as of and for the six months ended June 30, 2025, which are included as Exhibit 99.1. The historical financial statements of Akoya were previously filed in a post-effective amendment to Quanterix’s Form S-4 registration statement and are incorporated by reference rather than repeated here.